Amid concurrence and disagreement over various issues, SBSTTA28 ends in Nairobi ahead of CBD COP17 in Yerevan
The 28th meeting of the Subsidiary Body on Scientific, Technical and Technological Advice (SBSTTA28) to the Convention on Biological Diversity (CBD) concluded on 1 August 2026 in Nairobi, Kenya, after a six-day session
The meeting reached consensus on several scientific and technical matters supporting implementation of the Kunming-Montreal Global Biodiversity Framework (KMGBF)
A first global progress report, drawing on submissions from 129 countries, found that the world is not on track to meet most of the KMGBF's 2030 targets, citing inadequate finance and technology transfer to developing countries
The most contentious unresolved issue was synthetic biology — countries disagreed on regulatory flexibility for a proposed thematic action plan, whether to create new expert groups, and whether the plan should recognise nature's intrinsic value beyond its utility for scientific applications
Unresolved matters move to SBI-7 (Subsidiary Body on Implementation, 4-12 August 2026, also in Nairobi) before reaching COP17 delegates
CBD COP17 will convene 19-30 October 2026 in Yerevan, Armenia, to review KMGBF progress and decide further action
Convention on Biological Diversity (CBD) and Its Subsidiary Bodies
The CBD is a multilateral treaty opened for signature at the 1992 Rio Earth Summit (UNCED) and in force since December 1993, with three core objectives: conservation of biological diversity, sustainable use of its components, and fair and equitable sharing of benefits from genetic resources. SBSTTA is the CBD's standing scientific advisory body, established under Article 25 of the Convention, while SBI (Subsidiary Body on Implementation) reviews progress on implementation and provides guidance to the Conference of Parties (COP).
Key Details
- CBD has near-universal membership (196 parties); the United States has signed but not ratified it
- Article 25 establishes SBSTTA to provide the COP with timely scientific, technical, and technological advice
- The CBD operates alongside two supplementary protocols: the Cartagena Protocol on Biosafety (2000, on living modified organisms) and the Nagoya Protocol on Access and Benefit-Sharing (2010)
- India ratified the CBD in 1994 and enacted the Biological Diversity Act, 2002 as domestic implementing legislation, establishing the National Biodiversity Authority (NBA)
SBSTTA28 is the science-advisory step in the CBD's institutional pipeline — technical disagreements here (such as on synthetic biology) get escalated to SBI and ultimately require political resolution at COP, illustrating the multi-tiered structure of global biodiversity governance.
Kunming-Montreal Global Biodiversity Framework (KMGBF) and the 30x30 Target
The KMGBF was adopted at CBD COP15 in Montreal in December 2022 (the "Kunming" name reflects that China held the COP presidency though the meeting was relocated to Montreal). It replaced the Aichi Biodiversity Targets (2010-2020, mostly unmet) with a new set of goals for 2050 and targets for 2030.
Key Details
- KMGBF contains 4 long-term goals (for 2050) and 23 action-oriented targets (for 2030)
- Target 3 ("30x30") calls for effective conservation and management of at least 30% of the world's terrestrial, inland water, coastal, and marine areas by 2030 — up from the Aichi Target of 17% for land and 10% for marine areas
- Target 19 addresses biodiversity finance, calling for mobilising at least USD 200 billion/year by 2030 from all sources, including USD 20 billion/year to developing countries by 2025, rising to USD 30 billion/year by 2030
- Parties are required to submit National Biodiversity Strategy and Action Plans (NBSAPs) aligned with KMGBF targets
SBSTTA28's global progress report finding that the world is "not on track" on most 2030 targets directly concerns implementation of this framework, and citing inadequate finance/technology transfer echoes the KMGBF's own Target 19 finance goals — a recurring gap between developed and developing country positions in CBD negotiations.
Synthetic Biology Governance Under the CBD
Synthetic biology (engineering or redesigning organisms at the genetic level for novel functions) has been on the CBD agenda since COP13 (2016), which established an Ad Hoc Technical Expert Group to examine its implications for biodiversity conservation, distinct from but related to the Cartagena Protocol's coverage of living modified organisms (LMOs).
Key Details
- The CBD's approach applies a precautionary, case-by-case risk assessment framework rather than a blanket ban or blanket approval
- Disagreement over "nature's intrinsic value" reflects a broader philosophical divide in environmental governance between anthropocentric (nature as resource) and eco-centric (nature has inherent worth) framings, relevant to Indian environmental jurisprudence's own recognition of the "public trust doctrine" and rights-based approaches to nature
- India does not yet have a dedicated synthetic biology regulatory framework; GMO-adjacent activity is regulated under the Environment (Protection) Act, 1986 Rules and overseen by the Genetic Engineering Appraisal Committee (GEAC)
The failure to reach consensus on a synthetic biology action plan at SBSTTA28 shows how emerging biotechnologies are outpacing existing international regulatory frameworks, a governance gap that COP17 will need to address.
- SBSTTA28 held: 27 July - 1 August 2026, Nairobi, Kenya (six-day session)
- SBI-7 scheduled: 4-12 August 2026, Nairobi
- CBD COP17 scheduled: 19-30 October 2026, Yerevan, Armenia
- KMGBF adopted: December 2022, COP15, Montreal; contains 4 goals and 23 targets for 2030
- Global progress report analysed submissions from 129 countries
- 30x30 target (Target 3): conserve at least 30% of land, inland waters, coastal and marine areas by 2030
- KMGBF Target 19 finance goal: mobilise USD 200 billion/year by 2030, including USD 20-30 billion/year to developing countries